Treeway sees positive data results for ALS treatment

Thursday, December 10, 2015

Treeway, a biotech company developing therapies against amyotrophic lateral sclerosis (ALS), today announced the completion of two successful phase I trials with its lead compound TW001, a more patient-friendly oral formulation of the Japanese stroke and ALS therapy edaravone. [Read More]

Treeway, LACDR collaborate on ALS therapy development

Thursday, October 16, 2014

Treeway, a Netherlands-based, amyotrophic lateral sclerosis (ALS) R&D strategy-focused company, and the Leiden Academic Center for Drug Research (LACDR) at the University of Leiden, the Netherlands, have formed a collaboration focused on the optimization of clinical trial designs and data analysis for ALS through the use of population disease progression models. Both parties aim to obtain a better understanding of the disease by developing ALS physiology-based disease models and test the effect of interventions in the different identified pathways.

[Read More]